Aurinia Pharmaceuticals Business Summary

Aurinia Pharmaceuticals Inc. (AUPH) is a commercial-stage biopharmaceutical company that generates revenue primarily through the sale of LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis (LN). Its business model is bifurcated into direct commercial operations within the United States and a licensing-and-royalty structure internationally, most notably through a partnership with Otsuka Pharmaceutical Co., Ltd. for markets in Europe and Japan. For the 2026 fiscal year, the company has issued total revenue guidance of $315 million to $325 million, reflecting double-digit growth driven by expanded clinical guidelines and the advancement of its pipeline candidate, aritinercept (a dual BAFF/APRIL inhibitor). Aurinia competes in the specialized autoimmune market against GlaxoSmithKline (Benlysta), Roche/Genentech (Gazyva), and Novartis, distinguishing itself as the only provider of a dedicated oral calcineurin inhibitor for LN. The leadership team is headed by President and CEO Peter Greenleaf, who brings extensive experience from previous executive roles at Sucampo Pharmaceuticals, MedImmune, and BioDelivery Sciences. He is supported by CFO Joseph M. Miller, who oversees the company’s disciplined capital management, including a 2025 share repurchase program that reduced outstanding shares by approximately 12.2 million. The board of directors is chaired by Kevin Tang, President of Tang Capital Management and a veteran life sciences investor, whose appointment in 2024 signaled a shift toward aggressive commercial execution and shareholder alignment. Notable institutional backers include Tang Capital Management, BlackRock, and New Enterprise Associates (NEA), providing a stable foundation for the company’s focus on maximizing the LUPKYNIS lifecycle and expanding its immunology footprint.